Contact: Karen Stamm, (210) 450-2020

Swaminathan Padmanabhan, M.D., will give an overview of lymphoma.
Printer Friendly Format

Patients with lymphoma will get some tools for coping with their disease at a luncheon lecture series at the CTRC at The University of Texas Health Science Center at San Antonio starting Jan. 21.

Health Science Center faculty and staff will be the featured speakers and lunch will be provided at five Wednesday lectures in January and February. Each event will be held noon–1:30 p.m. in the Mabee Conference Room, on the fourth floor of the CTRC Grossman Building, 7979 Wurzbach. Topics and speakers for the lecture series are listed below:

• Jan. 21– Understanding Lymphoma
  Swaminathan Padmanabhan, M.D., director, Hematological Malignancies, CTRC
  
  
• Jan. 28 – Treatment Options
  Scott Soefje, Pharm.D., BCOP, director, Investigational Drug Section, CTRC
  

  Joel D. Marcus, Psy.D., will discuss the psychosocial aspects of lymphoma.

  
  
• Feb. 11 – Understanding Your Labs and Imaging Test
  Speaker to be announced
  
  
• Feb. 18 – Psychosocial Aspects
  Joel D. Marcus, Psy.D., director of Psychosocial Oncology, CTRC
  
  
• Feb. 25 – Tools of Survivorship
  Mary Jackson, M.S.N., R.N., OCN, director, Patient and Family Services CTRC
  
  Sponsors for the lecture series are the CTRC and the Leukemia and Lymphoma Society. To register call Lorrie Gutierrez at (210) 377-1775.

###
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI)-Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug studies program in the world. IDD has participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit http://ctrc.uthscsa.edu.